Physician profile
Deepak Sharma
NPI 1053956292
$3,060.51
in general payments reported to CMS, 2019-2025
35 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $620 · 2023: $522 · 2024: $998 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $420.89 | 2021-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $406.90 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.09 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $288.39 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $242.84 | 2021-2025 | |
| Lilly USA, LLC | $178.35 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $135.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $119.71 | 2022-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.11 | 2023-2025 | Xifaxan, Trulance |
| Indivior INC. | $93.92 | 2024 | Sublocade |
| Amarin Pharma, INC. | $75.83 | 2021 | |
| Abbvie INC. | $52.95 | 2022-2025 | |
| Orexo US, INC. | $42.83 | 2021-2023 | Zubsolv |
| Exact Sciences Corporation | $41.19 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $41.07 | 2024 | Inspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $39.34 | 2022 | |
| Currax Pharmaceuticals LLC | $30.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.95 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $27.94 | 2022 | |
| Medtronic, INC. | $26.66 | 2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.04 | 2025 | Caplyta |
| Organon LLC | $26.01 | 2023 | Nexplanon |
| Axsome Therapeutics, INC. | $25.76 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $25.38 | 2024 | |
| Hologic Sales and Service, LLC | $24.19 | 2024 | Aptima |
| Recordati_rare_diseases_inc. | $23.54 | 2025 | Isturisa |
| Ultragenyx Pharmaceutical INC. | $22.74 | 2023 | |
| Aimmune Therapeutics, INC. | $21.05 | 2024 | |
| Horizon Therapeutics Plc | $20.89 | 2021 | |
| Kyowa Kirin, INC. | $20.73 | 2023 | Crysvita |
| Lundbeck LLC | $17.85 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $17.54 | 2023 | Shingrix, Arexvy |
| Roche Diabetes Care, INC. | $16.74 | 2022 | |
| Lifescan, INC. | $15.80 | 2022 | |
| Abbott Laboratories | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.